Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – CNS tumours

1587 - Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: a French POLA network study.


28 Sep 2019


Poster Discussion – CNS tumours


Coline Montegut


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


C. Montegut1, J. Guillamo2, F. Ducray3, C. Dehais4, O. Chinot5, E.L. Cohen-Jonathan Moyal6, E. Le Rhun7, H. Loiseau8, R. Appay9, D. Figarella-Branger10, J. Delattre4, E. Tabouret11

Author affiliations

  • 1 Service De Neuro-oncologie, Assistance Publique Hopitaux de Marseille, 13005 - Marseille/FR
  • 2 Service De Neuro-oncologie,, Centre Hospitalier Universitaire Carémeau, Nimes/FR
  • 3 Neuro-oncology, Hospices civils de lyon Hôpital neurologique pierre wertheimer, 69500 - Bron/FR
  • 4 Service De Neurologie, Centre Hospitalier Universitaire Paris, La Pitié Salpêtrière-Charles Foix, Paris/FR
  • 5 Service De Neuro-oncologie, AP-HM - CHU La Timone Adulte, 13385 - Marseille/FR
  • 6 Département De Radiothérapie, Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 7 Neuro-oncology, Neurosurgery Department, Roger Salengro Hospital, 59037 - Lille/FR
  • 8 Service De Neuro-chirurgie, Centre Hospitalier Universitaire Bordeaux, Bordeaux/FR
  • 9 Service D'anatomie Et Cytologie Pathologiques Et De Neuropathologie, CHU de Marseille - Hôpital de la Timone, Marseille/FR
  • 10 Service D'anatomie Et Cytologie Pathologiques Et De Neuropathologie, CHU de Marseille - Hôpital de la Timone, 13385 - Marseille/FR
  • 11 Service De Neuro-oncologie, CHU La Timone Adultes, 13385 - Marseille/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1587


The characteristics of elderly patients with IDH-mutant (IDHm) high-grade gliomas (HGG) remain to be described. This study aims to describe characteristics and patterns of care of elderly patients with IDHm HGG included in the French POLA network dedicated to HGG.


The characteristics and patterns of care of elderly (≥70 years) patients IDHm HGG were compared to those of younger patients (<70 years) with IDHm gliomas and to those of elderly patients with IDH wild-type (IDHwt) gliomas.


Out of the 1433 HGG patients included, 119 (8.3%) occurred in elderly patients. Histology consisted of 1p/19q codeleted anaplastic oligodendroglioma (71.8%), anaplastic IDHm astrocytomas (12.8%) and IDHm glioblastoma (15.4%). Median age at diagnosis was 74 years (70.2-87.1), median Karnofsky Performans Status (KPS) was 80 (50-100). Treatments consisted of a wait and scan policy (7.7%), radiotherapy (RT) alone (7.7%), chemotherapy (CT) alone (41%), RT-CT (RT-TMZ: 25.6%, RT-PCV: 15.4%) or palliative care (2.6%). The clinical, radiological and histological presentations of elderly patients IDHm HGG were different from those of elderly patients IDHwt HGG. Compared to elderly patients IDHwt HGG, elderly patients IDHm were less frequently associated with cognitive impairment (p = 0.045), contrast enhancement (p = 0.01) and had a lower proliferative index (Ki67) (p = 0.005). In contrast, there was no difference regarding clinical, radiological and histological presentations of elderly and younger patients IDHm HGG but their management was different. Elderly patients IDHm less frequently underwent gross total resection (p = 0.002) and radiotherapy (p < 0.001). The median progression-free survival (PFS) and overall survival (OS) were longer for IDHm elderly patients (29.2 and 62.1 months respectively) than IDHwt elderly patients (8.2 and 13.2 months respectively) but shorter than younger IDHm patients (69 months and not reached respectively).


IDHm HGG in elderly show prolonged survival. However, their poorer outcome compared to younger IDHm gliomas may results from patient or tumor characteristics or from under-treatment, suggesting a role for geriatric assessment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

French POLA network.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.